CoChat
Cited by 18

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

JWH133 inhibits MPP+-induced inflammatory response and iron influx in astrocytes

Jia, Yi, Deng, Han, Qin, Qiuyu, Ma, ZeGang · 2020 · Neuroscience Letters

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neulet.2020.134779

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 35

  1. Lee, 2019, Parkinson’s disease-associated LRRK2- G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes, Acta Neuropathol. Commun., 7, 68, 10.1186/s40478-019-0716-4 · DOI
  2. Stojkovska, 2015, Parkinson’s disease and enhanced inflammatory response, Experimental biology and medicine (Maywood, N.J.), Exp. Biol. Med., 240, 1387, 10.1177/1535370215576313 · DOI
  3. Liu, 2018, Orexin-a exerts neuroprotective effects via OX1R in parkinson’s disease, Front. Neurosci., 12, 835, 10.3389/fnins.2018.00835 · DOI
  4. Yasuda, 2008, The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains, J. Neuroimmunol., 204, 43, 10.1016/j.jneuroim.2008.08.003 · DOI
  5. Forno, 1992, Astrocytes and Parkinson’s disease, Prog. Brain Res., 94, 429, 10.1016/S0079-6123(08)61770-7 · DOI · Paper page
  6. Kempuraj, 2017, Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration, Front. Cell. Neurosci., 11, 216, 10.3389/fncel.2017.00216 · DOI · Paper page
  7. Brough, 2015, Interleukin-1 as a pharmacological target in acute brain injury, Exp. Physiol., 100, 1488, 10.1113/EP085135 · DOI
  8. Cassano, 2017, Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target, Front. Neurosci., 11, 30, 10.3389/fnins.2017.00030 · DOI · Paper page
  9. Ma, 2019, Mechanisms of cannabinoid CB2 receptor- mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area, EBioMedicine, 42, 225, 10.1016/j.ebiom.2019.03.040 · DOI
  10. Walter, 2004, Cannabinoids and neuroinflammation, Br. J. Pharmacol., 141, 775, 10.1038/sj.bjp.0705667 · DOI · Paper page
  11. Price, 2009, WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease, Eur. J. Neurosci., 29, 2177, 10.1111/j.1460-9568.2009.06764.x · DOI · Paper page
  12. Huffman, 1999, 3-(1’,1’-Dimethylbutyl)-1- deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor, Bioorg. Med. Chem., 7, 2905, 10.1016/S0968-0896(99)00219-9 · DOI · Paper page
  13. Martin-Moreno, 2012, Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice, J. Neuroinflammation, 9, 8, 10.1186/1742-2094-9-8 · DOI · Paper page
  14. Hirsch, 2009, Iron transport in Parkinson’s disease, Parkinsonism Relat. Disord., 15, S209, 10.1016/S1353-8020(09)70816-8 · DOI
  15. Seo, 2016, Regulation of divalent metal transporter-1 by serine phosphorylation, Biochem. J., 473, 4243, 10.1042/BCJ20160674 · DOI
  16. Wetli, 2006, Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake, Chem. Biol., 13, 965, 10.1016/j.chembiol.2006.08.005 · DOI
  17. Abad-Rodriguez, 2000, Purification and structure of neurostatin, an inhibitor of astrocyte division of mammalian brain, J. Neurochem., 74, 2547, 10.1046/j.1471-4159.2000.0742547.x · doi:10.1046/j.1471-4159.2000.0742547.x
  18. Tenopoulou, 2007, Does the calcein-AM method assay the total cellular’ labile iron pool’ or only a fraction of it?, Biochem. J., 403, 261, 10.1042/BJ20061840 · DOI
  19. Xu, 2019, L-type calcium channels are involved in iron-induced neurotoxicity in primary cultured ventral mesencephalon neurons of rats, Neuroscience Bulletin, 1
  20. Di Marzo, 2015, Endocannabinoid signalling and the deteriorating brain, Nat. Rev. Neurosci., 16, 30, 10.1038/nrn3876 · DOI · Paper page
  21. Chen, 2017, Brain cannabinoid receptor 2: expression, function and modulation, Acta Pharmacol. Sin., 38, 312, 10.1038/aps.2016.149 · DOI · Paper page
  22. Benito, 2008, Cannabinoid CB2 receptors in human brain inflammation, Br. J. Pharmacol., 153, 277, 10.1038/sj.bjp.0707505 · DOI · Paper page
  23. Facchinetti, 2003, Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide, Glia, 41, 161, 10.1002/glia.10177 · DOI · Paper page
  24. Ramirez, 2005, Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation, The Journal of neuroscience: the official journal of the Society for Neuroscience, 25, 1904, 10.1523/JNEUROSCI.4540-04.2005 · DOI · Paper page
  25. Navarrete, 2018, Cannabinoid CB1 and CB2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with parkinson’s disease, Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 15, 459, 10.1007/s13311-018-0603-x · DOI
  26. Neal, 2018, Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration, Biochimica et biophysica acta. Molecular basis of disease, 1864, 432, 10.1016/j.bbadis.2017.11.004 · DOI · Paper page
  27. Blandini, 2012, Animal models of Parkinson’s disease, FEBS J., 279, 1156, 10.1111/j.1742-4658.2012.08491.x · DOI · Paper page
  28. Kempuraj, 2018, Glia maturation factor and mast cell-dependent expression of inflammatory mediators and proteinase activated Receptor-2 in neuroinflammation, J. Alzheimers Dis., 66, 1117, 10.3233/JAD-180786 · DOI
  29. Howlett, 2002, The cannabinoid receptors, Prostaglandins Other Lipid Mediat., 68- 69, 619, 10.1016/S0090-6980(02)00060-6 · DOI · Paper page
  30. Saadat, 2015, Is the 1254T&C polymorphism in the DMT1 gene associated with Parkinson’s disease?, Neurosci. Lett., 594, 51, 10.1016/j.neulet.2015.03.054 · DOI
  31. He, 2011, DMT1 polymorphism and risk of Parkinson’s disease, Neurosci. Lett., 501, 128, 10.1016/j.neulet.2011.07.001 · DOI
  32. Wang, 2017, Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice, Oncotarget, 8, 47284, 10.18632/oncotarget.17618 · DOI
  33. Moos, 2007, Iron trafficking inside the brain, J. Neurochem., 103, 1730, 10.1111/j.1471-4159.2007.04976.x · DOI · Paper page
  34. Burkhart, 2016, Expression of Iron-Related Proteins at the Neurovascular Unit Supports Reduction and Reoxidation of Iron for Transport Through the Blood-Brain Barrier, Mol. Neurobiol., 53, 7237, 10.1007/s12035-015-9582-7 · DOI
  35. Kim, 2011, Influence of DMT1 and iron status on inflammatory responses in the lung, American journal of physiology, Lung cellular and molecular physiology, 300, L659, 10.1152/ajplung.00343.2010 · DOI

Cited by

See all 18

Metadata

Authors
Jia, Y., Deng, H., Qin, Q., & Ma, Z.
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
2020-02
Volume
720
Pages
134779
ISSN
0304-3940
Cited by
18
References
10
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.